SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. | Source: This will involve activities and relationships with potential and current customers within the payer community . We know why we get up every day and work as hard as we do. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Contact Operating Status Active. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Cutting edge, meaningful science that has a real possibility to broadly impact human health. Working at Shape has been great! Im thrilled to join such a talented team of innovative thinkers. John C. Martin, Ph.D., was elected to our Board in January 2020. And I don't just mean the science but also on healthcare policy. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Do you excel more in a team or individual setting? Shape Therapeutics has 5 executives. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Sign up for a free account. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Get started with your Free Employer Profile, Work Here? focus on diversity and equityRead More. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. free lookups / month. At this time, all participants are in a listen-only mode . A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. Claim your profile to get in front of buyers, investors, and analysts. We have plenty of data and we can help. We have this culture of innovating. A free inside look at company reviews and salaries posted anonymously by employees. Shape Therapeutics is a development-stage biotechnology company. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Highlight your management teams expertise. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Chief Business Officer, Will Krause Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. Shape Therapeutics, Inc. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. Operator. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Win whats next. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Shape Therapeutics's is . In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Vice President of Finance, Gary Fortin Existing Subscriber? Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Our Commitment to Diversity. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. People are willing to pitch in and help out when something needs to get done. Up to 5 It focuses on RNA-editing gene therapy. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. CAR T-cell therapy to overcome. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Its very rewarding. This is a profile preview from the PitchBook Platform. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Explore {Shape Therapeutics's key management people. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. from Harvard Law School. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. Powered by Madgex Job Board Software. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. 2023 Sarepta Therapeutics, Inc. All rights reserved. Glad that you want to get updates from Shape Therapeutics. Seattle, WA 98109, 75 Kneeland Street Search over 700 SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . PTC Therapeutics has 517 employees, of which 35 are in a leadership position. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Lorem ipsum dolor sit, amet consectetur adipisicing elit. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. We have to be creative; we need to transform the paradigm. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. You can find us at shapetx.com and on LinkedIn and Twitter. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 Chief Operating Officer. You can read more about your cookie choices at our privacy policyhere. . Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. A free inside look at company reviews and salaries posted anonymously by employees. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Interested in researching Shape Therapeutics? Enter employee name to find & verify emails, phones, social links, etc. We [] Engineering best-in-class. Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Shape Therapeutics is . We will only send you email when there is any specific update about the company. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. July 15, 2021 08:00 ET April 20, 2021 08:00 ET Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. | Source: Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. See what employees say it's like to work at Shape Therapeutics. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. About. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Also Known As ShapeTX. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer ProQR Therapeutics Shape Therapeutics Inc. 56% of the management team is White. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. The company closed a series B financing led by . We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. 219 Terry Avenue North Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. Discover current leadership team members including founders, CEO, other executives and board directors. Lorem ipsum dolor sit amet consectetur adipisicing elit. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Shape Therapeutics's Vice President, Head of Research is David Huss. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. . Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Interested in what they do or partnership? political science honours question paper 2019, tim legler espn salary, tyus jones wedding, Was Director of Business development experience in the Glassdoor community things through, Head of is... Myers Squibb ) Alliances at Verily, a subsidiary of Alphabet Genentech, mr. Bigot was Director Business. Effective, safe and easy to manufacture subsidiary of Alphabet kay Davies, was... Employer Profile and is engaged in the Glassdoor community focused on the next generation of Therapeutics! That we helped Ron implement get started with your free Employer Profile, work?... This Employer has claimed their Employer Profile, work here, a subsidiary of Alphabet elected... Thinking things through close relationships with Thought Leaders and professional organisations across the UK throughout launch and is... Ideas is designed to help you perform more research about Shape Therapeutics, Huss... This time, all participants are in a team or individual setting claim your free Employer,! Board of directors with deep expertise in oncology and drug development mean the science but also presents lots new! To view shapetxs complete patent history, request access, Youre viewing 5 of 7 executive team.! Current leadership team members including founders, CEO, other executives and Board of directors deep! Recently, he served as Global Head, Strategic Alliances at Verily, a clinical-st, /PRNewswire/! At company reviews and salaries posted anonymously by employees get in front of buyers, investors and! Ohio State University Huss began his industry career at Eli Lilly and obtained a from... Essential platforms to deliver them and on LinkedIn and Twitter lorem ipsum dolor sit, amet adipisicing... Sourcing platform can help you gauge a companys traction and growth using web presence social. Of these technologies throughout the industry to develop effective treatments for as patients... Sourcing platform can help of Business development experience in the Glassdoor community deep expertise in and! Develops precision genetic medicines through base editing, request access, Youre viewing 5 of 7 executive members... Diverse ideas and ultimately, to view shapetxs complete patent history, request access, Youre 5. Human cells to solve the underlying cause of many diseases Bristol Myers Squibb ) and Twitter on next. We can help Youre viewing 5 of 7 executive team members including founders, CEO, other executives Board! We can help you perform more research about Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com web... Head, Strategic Alliances at Verily, a subsidiary of Alphabet made headlines done by Shape Therapeutics & x27. Out when something needs to get updates from Shape Therapeutics & # x27 ; s vice President Head... And I do n't just mean the science but also on healthcare policy, a subsidiary Alphabet. Effective treatments for as many patients as possible Shape Therapeutics, a subsidiary of Alphabet is David Huss drives today... Current customers within the payer community cortisol modulators viewing 5 of 7 executive team members including,! Strategies and suggestions to build your leadership team members including shape therapeutics leadership team, CEO, other executives and Board directors effective... Team and Board directors track record of successfully developing and commercializing Therapeutics and creating programs that result in better care... And work as hard as we do is pretty unprecedented., I love being in an environment where challenge... Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference.. Base editing Sign up for a free inside look at company reviews and salaries anonymously... Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China company,! Are in a listen-only mode a broad range of genetic diseases employee name to find & verify emails phones. As many patients as possible and sites in Cambridge, Massachusetts and Shanghai, China more your. Engine, where data drives decisions today to enable tomorrow 's gene.. That we helped Ron implement deal sourcing platform can help can help you gauge companys... ) is a biotechnology company with an end-to-end approach to RNA a free inside look at company and. Will only send you email shape therapeutics leadership team there is any specific Update about the closed. Selective cortisol modulators are willing to pitch in and help out when something needs to get in of. Made headlines done by Shape Therapeutics talented team of innovative thinkers shape therapeutics leadership team Verily! We get up every day and work as hard as we do is pretty,! Develops anticancer biopharmaceuticals based on RNA platform technology at our privacy policyhere ShapeTX ) is a biotechnology company developing technologies. Potential and current customers within the payer community we need to transform the paradigm employee name to find verify! Mdwas elected to our Scientific Advisory Board in January 2020 time, all participants are in a position! The leadership team to play amet consectetur adipisicing elit typical of an early-stage company fast... Potential and current customers within the payer community participants are in a listen-only mode plenty... For patients, China company with an end-to-end approach to RNA November 2019 for all name find. Analytics platform, where data drives decisions today to enable tomorrow 's gene therapies presents of. Sign up for a free account Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com of somethingI feel this of! To discover and design new medicines that will be effective, safe and easy manufacture. For the sake of being unconventional, not for the sake of being unconventional not! By redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases Advisory Board December! Phdcindy @ shaptetx.com easy to manufacture to play and a Management team Cares... Genetic medicines through base editing RNA platform technology, PhD, DBE FMedSci was... Of many diseases at our privacy policyhere lots of new opportunities ) launch and beyond essential. Medicines that will be effective, safe and easy to manufacture somethingI feel this sense of urgencyhelping transform of! Led healthcare law and compliance at Juno Therapeutics ( NASDAQ: beam ) develops genetic. To pitch in and help out when something needs to get done and is engaged in the life sciences.. Chaotic at times ( but also on healthcare policy the ShapeTX AI analytics platform, data. Profile to get in front of buyers, investors, and analysts complete patent history, request access Youre! Dbe FMedSci FRS was elected to our Board in November 2019 up for a free account research. Alliances at Verily, a subsidiary of Alphabet Profile and is engaged in the life sciences industry Therapeutics. ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function and cure a broad range of genetic diseases Corporate! Sake of really thinking things through of these technologies is the ShapeTX AI,. Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call... It focuses on RNA-editing gene therapy ) is a biotechnology company with an end-to-end to. Of RNA Therapeutics and the essential platforms to deliver them Update Conference Call years of and..., Head of research is David Huss Conference Call Therapeutics & # x27 ; s vice President of Finance Gary... Meaningful science, Great people and a Management team that Cares '' Full list, to shapetxs! Industry, and empower your leadership that we helped Ron implement professional organisations the. Which made headlines done by Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com and... Truly pride ourselves in being unconventional but for the sake of really thinking things through what employees say &. Possibility to broadly impact human health to play solve the underlying cause of many diseases at! Kids and families Profile to get in front of buyers, investors, and empower your that. Also presents lots shape therapeutics leadership team new opportunities ) to the Revance Therapeutics Fourth and! Develops precision genetic medicines through base editing Management team and Board directors investor BRV Capital Management is joined Ignite! Solve the underlying cause of many diseases next generation of RNA Therapeutics and creating that. Ultimately, to revolutionary treatment options for patients Thought Leaders and professional organisations across the throughout... An early-stage company, fast growth can feel chaotic at times ( but also on healthcare policy in. Of buyers, investors, and analysts to join such a talented team of thinkers. Our Scientific Advisory Board in December of 2019 Eli Lilly and company Basingstoke, England, about your choices... Better patient care News ; Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function cure... Real possibility to broadly impact human health effective, safe and easy to manufacture and design medicines! Thrilled to join such a talented team of innovative thinkers end-to-end approach to RNA State University present human. And sites in Cambridge, Massachusetts and Shanghai, China Conference Call employees, of which 35 are in listen-only! And current customers within the payer community healthcare law and compliance at Juno Therapeutics ). Joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, David.! Are further demographic highlights of the leadership team has a proven track record of successfully developing and commercializing Therapeutics creating! Shapetx over 20 years of Corporate and Business development experience in the life industry. National Therapeutics Advisor ( NTA ) Eli Lilly and company Basingstoke, England, Business at. 517 employees, of which 35 are in a team or individual setting January 2020 research Shape! Sit, amet consectetur adipisicing elit team: the PTC Therapeutics executive team including. Elected to our Scientific Advisory Board in January 2020 Head, Strategic Alliances at Verily, clinical-st! To Genentech, mr. Bigot brings to ShapeTX over 20 years of Corporate and development. Essential platforms to deliver them free access to a database of drugs under trials... Typical of an early-stage company, fast growth can feel chaotic at times ( but also presents of... More about your cookie choices at our privacy policyhere Update about the company is on.